The annual report of 18 pharmaceutical and biological enterprises is expected to be happy, with the growth rate of more than 10% in the same and month on month!

[pharmaceutical network industry trends] it is only a few days before 2020 At present, the release of 2019 annual report of A-share listed companies has entered the fast lane According to industry statistics, as of December 20, 560 listed companies in Shanghai and Shenzhen have disclosed the performance forecast of 2019 annual report, among which 271 listed companies have performance forecast, accounting for 48.39% The companies with good performance mainly focus on chemical industry (28), mechanical equipment (28), electronics (22), computer (22), medicine and Biology (18), light industry manufacturing (17) and other industries The industry pointed out that since this year, with the promotion of tax reduction and fee reduction policies, the tax revenue ratio of A-share companies may fall to less than 7.3%, and more than 40% of manufacturing taxpayers spend their dividends on R & D investment, which may be an important reason for the annual performance growth of some companies In addition, although the company that has announced the annual report is just the tip of the iceberg, the overall growth of the industry is quite good As far as the pharmaceutical and biological industry is concerned, since this year, affected by policies such as volume purchasing, the industry pattern has changed, and the leading enterprises with high industry prosperity have a better space for growth At present, companies with a year-on-year and a month on month growth rate of more than 10% in performance forecast include Jiuzhou pharmaceutical, berry gene, shuoshi biology, kailaiying, mede medical, Xiangsheng medical and other enterprises Jiuzhou Pharmaceutical Co., Ltd predicted that the net profit in 2019 will be 244-283 million yuan It is estimated that the net profit in 2019 will increase 55% - 80% year on year, and the net profit will increase 225.31% - 343.76% month on month According to the data, Jiuzhou pharmaceutical is a high-tech enterprise providing one-stop R & D, production and sales services for global chemical APIs and pharmaceutical intermediates The main business of Kyushu pharmaceutical industry includes two aspects First, it is mainly engaged in characteristic APIs, providing technological innovation and commercial production for chemical APIs and pharmaceutical intermediates; second, it is a one-stop cdmo service for pharmaceutical enterprises in R & D and production of innovative drugs On October 31, berry gene released the full year performance forecast of 2019, which shows that in the whole year of 2019, it is expected that the net profit attributable to shareholders of listed companies will reach 410 million-440 million yuan, a year-on-year increase of 52.93% - 64.12%, and the net profit is expected to increase 51.53% - 98.59% month on month According to the data, berry gene is a R & D biotech company dedicated to applying high-throughput gene sequencing technology to provide "non-invasive" overall solutions for clinical medical disease screening and diagnosis On November 14, shuoshi biology released the performance forecast The company expects the net profit attributable to the shareholders of the listed company from January to December 2019 to be 82.92m-92.88m, with a year-on-year change of 43.89% to 61.19%, and the net profit is expected to increase by 68.18% - 118.71% month on month According to the data, shuoshi biology is a high-tech enterprise mainly engaged in in in vitro diagnostic reagents such as nucleic acid molecular diagnostic reagents, dry chemical diagnostic reagents, nucleic acid purification reagents and supporting detection instruments According to the 2019 performance forecast disclosed by carling carling, the company expects to make a profit of 535.37 million yuan to 599.61 million yuan in 2019, an increase of 25% - 40% over the same period of last year, and the expected net profit will increase by 23.07% - 69.90% month on month According to the data, kelleying is a leading cdmo solution provider in the global industry It is mainly committed to technological innovation and commercial application of global pharmaceutical technology, and provides one-stop CMC services for large and medium-sized pharmaceutical enterprises and biotechnology enterprises at home and abroad MedTech medical is expected to make a profit of 64-68 million yuan in 2019, an increase of 15.00% - 22.19% over the same period last year, and an expected net profit growth of 7983.84% - 8660.80% month on month According to the data, MedTech medical is mainly engaged in the research and development, production and sales of medical consumables intelligent equipment, providing medical consumables manufacturers with intelligent manufacturing related equipment and systems The net profit of Xiangsheng medical in 2019 is expected to exceed 100 million yuan, an increase of 8.00% - 18.00% over the same period of last year, and an increase of 82.59% - 124.35% on a month on month basis According to the data, Xiangsheng medical mainly engaged in the research, development, production and sales of ultrasound medical imaging equipment, including color ultrasound and black-and-white ultrasound.